[1]
|
Gerecke, C., Fuhrmann, S., Strifler, S., Schmidt-Hieber, M., Einsele, H. and Knop, S. (2016) The Diagnosis and Treatment of Multiple Myeloma. DÄ International, 113, 470-476. https://doi.org/10.3238/arztebl.2016.0470
|
[2]
|
Vande Broek, I., Vanderkerken, K., Van Camp, B. and Van Riet, I. (2008) Extravasation and Homing Mechanisms in Multiple Myeloma. Clinical & Experimental Metas-tasis, 25, 325-334. https://doi.org/10.1007/s10585-007-9108-4
|
[3]
|
Sevcikova, S., Minarik, J., Stork, M., Jelinek, T., Pour, L. and Hajek, R. (2019) Extramedullary Disease in Multiple Myeloma—Controversies and Future Directions. Blood Reviews, 36, 32-39. https://doi.org/10.1016/j.blre.2019.04.002
|
[4]
|
Li, G., Song, Y.P., Lv, Y., Li, Z.Z. and Zheng, Y.H. (2021) Clinical Characteris-tics and Prognostic Analysis of Multiple Myeloma with Extramedullary Disease: A SEER-Based Study. Journal of Oncology, 2021, Article ID: 6681521.
https://doi.org/10.1155/2021/6681521
|
[5]
|
Sheth, N., Yeung, J. and Chang, H. (2009) p53 Nuclear Accumulation Is Associated with Extramedullary Progression of Multiple Myeloma. Leukemia Research, 33, 1357-1360. https://doi.org/10.1016/j.leukres.2009.01.010
|
[6]
|
Deng, S., Xu, Y., An, G., et al. (2015) Features of Extramedullary Disease of Multiple Myeloma: High Frequency of p53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma, Myeloma and Leukemia, 15, 286-291. https://doi.org/10.1016/j.clml.2014.12.013
|
[7]
|
Billecke, L., Murga Penas, E.M., May, A.M., et al. (2013) Cytogenetics of Extramedullary Manifestations in Multiple Myeloma. British Journal of Haematology, 161, 87-94. https://doi.org/10.1111/bjh.12223
|
[8]
|
Qu, X., Chen, L., Qiu, H., et al. (2015) Extramedullary Manifestation in Mul-tiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance. BioMed Research International, 2015, Article ID: 787809.
https://doi.org/10.1155/2015/787809
|
[9]
|
Besse, L., Sedlarikova, L., Greslikova, H., et al. (2016) Cytogenetics in Multiple Mye-loma Patients Progressing into Extramedullary Disease. European Journal of Haematology, 97, 93-100. https://doi.org/10.1111/ejh.12688
|
[10]
|
Szabo, A.G., Gang, A.O., Pedersen, M.Ø., Poulsen, T.S., Klausen, T.W. and Nørgaard, P. (2016) Overexpression of c-myc Is Associated with Adverse Clinical Features and Worse Overall Survival in Multiple Myeloma. Leu-kemia & Lymphoma, 57, 2526-2534. https://doi.org/10.1080/10428194.2016.1187275
|
[11]
|
Wang, S.Y., Hao, H.L., Deng, K., et al. (2012) Expression Levels of Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) and Focal Adhesion Kinase in Patients with Multiple Myeloma and Their Relationship to Clinical Stage and Extramedullary Infiltration. Leukemia & Lymphoma, 53, 1162-1168.
https://doi.org/10.3109/10428194.2011.647311
|
[12]
|
Rasmussen, T., Kuehl, M., Lodahl, M., Johnsen, H.E. and Dahl, I.M. (2005) Possible Roles for Activating RAS Mutations in the MGUS to MM Transition and in the Intramedullary to Extramedullary Transition in Some Plasma Cell Tumors. Blood, 105, 317-323. https://doi.org/10.1182/blood-2004-03-0833
|
[13]
|
Da Vià, M.C., Solimando, A.G., Garitano-Trojaola, A., et al. (2020) CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist, 25, 112-118. https://doi.org/10.1634/theoncologist.2019-0356
|
[14]
|
Smetana, J., Oppelt, J., Štork, M., Pour, L. and Kuglík, P. (2018) Chro-mothripsis 18 in Multiple Myeloma Patient with Rapid Extramedullary Relapse. Molecular Cytogenetics, 11, Article No. 7. https://doi.org/10.1186/s13039-018-0357-5
|
[15]
|
Dahl, I.M., Rasmussen, T., Kauric, G. and Husebekk, A. (2002) Differential Expression of CD56 and CD44 in the Evolution of Extramedullary Myeloma. British Journal of Haematology, 116, 273-277.
https://doi.org/10.1046/j.1365-2141.2002.03258.x
|
[16]
|
王路, 张翼鷟. 伴髓外病变的多发性骨髓瘤研究进展[J]. 中国实验血液学杂志, 2016, 24(3): 945-948.
|
[17]
|
Pesapane, A., Ragno, P., Selleri, C. and Montuori, N. (2017) Recent Advances in the Func-tion of the 67 kDa Laminin Receptor and Its Targeting for Personalized Therapy in Cancer. Current Pharmaceutical Design, 23, 4745-4757.
https://doi.org/10.2174/1381612823666170710125332
|
[18]
|
Ullah, T.R. (2019) The Role of CXCR4 in Multiple Myeloma: Cells’ Journey from Bone Marrow to beyond. Journal of Bone Oncology, 17, Article ID: 100253. https://doi.org/10.1016/j.jbo.2019.100253
|
[19]
|
Handa, H., Kuroda, Y., Kimura, K., et al. (2017) Long Non-Coding RNA MALAT1 Is an Inducible Stress Response Gene Associated with Extramedullary Spread and Poor Prognosis of Multiple Myeloma. British Journal of Haematology, 179, 449-460. https://doi.org/10.1111/bjh.14882
|
[20]
|
Sun, Y., Jiang, T., Jia, Y., Zou, J., Wang, X. and Gu, W. (2019) LncRNA MALAT1/miR-181a-5p Affects the Proliferation and Adhesion of Myeloma Cells via Regulation of Hippo-YAP Signaling Pathway. Cell Cycle, 18, 2509-2523.
https://doi.org/10.1080/15384101.2019.1652034
|
[21]
|
Jagosky, M.H. and Usmani, S.Z. (2020) Extramedullary Disease in Multi-ple Myeloma. Current Hematologic Malignancy Reports, 15, 62-71. https://doi.org/10.1007/s11899-020-00568-3
|
[22]
|
Gagelmann, N., Eikema, D.J., Koster, L., et al. (2019) Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 25, 2134-2142. https://doi.org/10.1016/j.bbmt.2019.07.004
|
[23]
|
Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. and Lazzarino, M. (2010) Incidence, Presenting Features and Outcome of Extrame-dullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients. Annals of Oncology, 21, 325-330. https://doi.org/10.1093/annonc/mdp329
|
[24]
|
Beksac, M., Seval, G.C., Kanellias, N., et al. (2020) A Real World Multicenter Ret-rospective Study on Extramedullary Disease from Balkan Myeloma Study Group and Barcelona University: Analysis of Parameters That Improve Outcome. Haematologica, 105, 201-208. https://doi.org/10.3324/haematol.2019.219295
|
[25]
|
Gagelmann, N., Eikema, D.J., Iacobelli, S., et al. (2018) Impact of Extramedullary Disease in Patients with Newly Diagnosed Multiple Myeloma Un-dergoing Autologous Stem Cell Transplantation: A Study from the Chronic Malignancies Working Party of the EBMT. Haematologica, 103, 890-897.
|
[26]
|
Dimopoulos, M.A., Hillengass, J., Usmani, S., et al. (2015) Role of Magnetic Resonance Imaging in the Manage-ment of Patients with Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 33, 657-664.
https://doi.org/10.1200/JCO.2014.57.9961
|
[27]
|
Long, X., Xu, Q., Lou, Y., et al. (2020) The Utility of Non-Invasive Liquid Bi-opsy for Mutational Analysis and Minimal Residual Disease Assessment in Extramedullary Multiple Myeloma. British Journal of Haematology, 189, e45-e48.
https://doi.org/10.1111/bjh.16440
|
[28]
|
Mangiacavalli, S., Pompa, A., Ferretti, V., et al. (2017) The Possible Role of Burden of Therapy on the Risk of Myeloma Extramedullary Spread. Annals of Hematology, 96, 73-80. https://doi.org/10.1007/s00277-016-2847-z
|
[29]
|
Venkatesulu, B., Mallick, S., Giridhar, P., Upadhyay, A.D. and Rath, G.K. (2018) Pattern of Care and Impact of Prognostic Factors on the Outcome of Head and Neck Extramedullary Plasmacytoma: A System-atic Review and Individual Patient Data Analysis of 315 Cases. European Archives of Oto-Rhino-Laryngology, 275, 595-606.
https://doi.org/10.1007/s00405-017-4817-z
|
[30]
|
Li, J., Shen, K.N., Huang, W.R., et al. (2014) Autologous Stem Cell Transplant Can Overcome Poor Prognosis in Patients with Multiple Myeloma with Extramedullary Plasmacytoma. Leukemia & Lymphoma, 55, 1687-1690.
https://doi.org/10.3109/10428194.2013.853296
|
[31]
|
Avet-Loiseau, H., Leleu, X., Roussel, M., et al. (2010) Bortezomib plus Dexamethasone Induction Improves Outcome of Patients with t(4; 14) Myeloma but Not Outcome of Patients with del(17p). Journal of Clinical Oncology, 28, 4630-4634. https://doi.org/10.1200/JCO.2010.28.3945
|
[32]
|
Montefusco, V., Gay, F., Spada, S., et al. (2020) Outcome of Paraosseous Extra-Medullary Disease in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. Haematologica, 105, 193-200.
https://doi.org/10.3324/haematol.2019.219139
|
[33]
|
Yan, Z., Cao, J., Cheng, H., et al. (2019) A Combination of Humanised An-ti-CD19 and Anti-BCMA CAR T Cells in Patients with Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase 2 Trial. The Lancet Haematology, 6, e521-e529. https://doi.org/10.1016/S2352-3026(19)30115-2
|
[34]
|
Wu, C., Zhang, L., Brockman, Q.R., Zhan, F. and Chen, L. (2019) Chimeric Antigen Receptor T Cell Therapies for Multiple Myeloma. Journal of Hematology & Oncology, 12, Article No. 120.
https://doi.org/10.1186/s13045-019-0823-5
|
[35]
|
Lin, Q., Zhao, J., Song, Y. and Liu, D. (2019) Recent Updates on CAR T Clini-cal Trials for Multiple Myeloma. Molecular Cancer, 18, Article No. 154. https://doi.org/10.1186/s12943-019-1092-1
|